Thursday, January 06, 2022 11:44:18 PM
The Goldman-Sachs healthcare conference Q&A this afternoon with S. Bancel was excellent and reaffirms my belief in the long term success of Moderna. Three major clinical readouts are coming this year. And I still don't understand the street's tepid reaction to the flu vaccine results; the data were really good. Also good news: Moderna & Vertex are moving forward (lab --> clinic) with the inhaled mRNA therapy for Cystic Fibrosis.
-
The Moderna CEO expects another round of boosters will be necessary in the fall of 2022. He said governments, including the U.K. and South Korea, are already ordering the shots in preparation.
"I still believe we're going to need boosters in the fall of '22 and forward," Bancel said, adding that people who are older or have underlying health conditions might need annual boosters for years to come.
"We have been saying that we believe first this virus is not going away," Bancel said. "We're gonna have to live with it."
-
The Moderna CEO expects another round of boosters will be necessary in the fall of 2022. He said governments, including the U.K. and South Korea, are already ordering the shots in preparation.
"I still believe we're going to need boosters in the fall of '22 and forward," Bancel said, adding that people who are older or have underlying health conditions might need annual boosters for years to come.
"We have been saying that we believe first this virus is not going away," Bancel said. "We're gonna have to live with it."
Recent MRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:57:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 01:47:23 PM
- Moderna Recognized by TIME as One of the World's Most Impactful Companies • ACCESS Newswire • 05/12/2026 09:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Moderna (MRNA) Shares Surge After U.S. Passenger Tests Positive for Hantavirus • IH Market News • 05/11/2026 10:38:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 10:06:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:06:08 PM
- Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 • ACCESS Newswire • 05/06/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 09:25:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/01/2026 08:10:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 03:44:50 PM
- Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates • ACCESS Newswire • 05/01/2026 10:30:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:30:03 PM
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate • ACCESS Newswire • 04/21/2026 11:01:00 PM
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting • ACCESS Newswire • 04/21/2026 02:00:00 PM
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 04/21/2026 01:40:00 PM
- Moderna to Present at Upcoming Conferences in May 2026 • ACCESS Newswire • 04/21/2026 11:00:00 AM
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting • ACCESS Newswire • 04/17/2026 07:00:00 PM
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 • ACCESS Newswire • 04/15/2026 11:00:00 AM
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 • ACCESS Newswire • 04/06/2026 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:45:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/16/2026 08:32:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 08:31:50 PM
